
The lecture by Robert Fischer answers why a relative deficiency of luteinizing hormone develops in a subset of patients during controlled ovarian stimulation, and in which clinical situations it is worth restoring it with recombinant LH. He frames LH deficiency not as a rare exception but as a predictable consequence of modern pituitary-suppression protocols.
The starting point is the two-cell, two-gonadotropin model of folliculogenesis. LH acts on theca cells to drive androgen synthesis, and these androgens are aromatized into estrogens in granulosa cells under the influence of FSH. Without sufficient LH activity this substrate pathway weakens, and follicular maturation suffers even when the FSH dose is adequate.
Against the background of pituitary desensitization with GnRH agonists and antagonists, endogenous LH in some patients falls below the threshold required for full steroidogenesis. This iatrogenic deficiency matters most in women with intrinsically low LH activity, in older patients, and when the response to FSH-only stimulation is suboptimal or slow.
Fischer builds the rationale for adding LH around a 2017 meta-analysis that pooled data on the combined use of FSH and recombinant LH. Without citing individual numerical results, he lays out the logic of the evidence: in defined subgroups, restoring LH is associated with a more favorable cycle course and helps correct an inadequate response.
He also examines the choice of endpoint used to judge the benefit of the intervention. The number of retrieved oocytes is treated as a practical and reproducible marker of the stimulation outcome, although the author stresses the need to weigh it against oocyte maturity, embryo quality and, ultimately, the pregnancy rate.
The practical section addresses the clinical scenarios in which adding recombinant LH is most justified: hypogonadotropic states, patients of advanced reproductive age, an unexpectedly weak response in a previous cycle, and signs of slow follicular growth on monitoring. Fischer offers reference points for the decision rather than a rigid universal algorithm.
The take-home message for the clinic is that assessing LH status should become part of protocol planning rather than a belated reaction to failure. Timely identification of patients with relative LH deficiency and personalized addition of recombinant LH help improve cycle efficiency in those for whom standard FSH monotherapy does not deliver a sufficient result. In this way, adding LH becomes a deliberate clinical decision matched to the individual patient's phenotype rather than a routine step.
When FSH alone is not enough: recognizing LH deficiency in stimulation and adding recombinant LH in time.
The viewer will be able to explain how pituitary suppression in stimulation protocols leads to relative LH deficiency and impairs follicular steroidogenesis.
The viewer will be able to use the two-cell, two-gonadotropin model to justify the role of LH in androgen synthesis and subsequent aromatization to estrogens.
The viewer will learn to recognize the clinical scenarios in which adding recombinant LH is most justified, including advanced age and poor response.
The viewer will be able to interpret oocyte yield correctly as an outcome marker, weighing it against oocyte maturity and embryo quality.